JP2025515671A - Ｃｏｔを調節するための化合物の固体形態 - Google Patents

Ｃｏｔを調節するための化合物の固体形態 Download PDF

Info

Publication number
JP2025515671A
JP2025515671A JP2024565314A JP2024565314A JP2025515671A JP 2025515671 A JP2025515671 A JP 2025515671A JP 2024565314 A JP2024565314 A JP 2024565314A JP 2024565314 A JP2024565314 A JP 2024565314A JP 2025515671 A JP2025515671 A JP 2025515671A
Authority
JP
Japan
Prior art keywords
formula
degrees
solid form
inhibitors
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515671A5 (enExample
Inventor
アーネスト エー． カッラ，
リナ チャン，
ローランド ディー． サイトウ，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2025515671A publication Critical patent/JP2025515671A/ja
Publication of JP2025515671A5 publication Critical patent/JP2025515671A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024565314A 2022-05-12 2023-05-10 Ｃｏｔを調節するための化合物の固体形態 Pending JP2025515671A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341289P 2022-05-12 2022-05-12
US63/341,289 2022-05-12
PCT/US2023/021659 WO2023220123A1 (en) 2022-05-12 2023-05-10 Solid forms of a compound for modulating cot

Publications (2)

Publication Number Publication Date
JP2025515671A true JP2025515671A (ja) 2025-05-20
JP2025515671A5 JP2025515671A5 (enExample) 2026-05-18

Family

ID=86710687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565314A Pending JP2025515671A (ja) 2022-05-12 2023-05-10 Ｃｏｔを調節するための化合物の固体形態

Country Status (9)

Country Link
US (1) US20240174702A1 (enExample)
EP (1) EP4522268A1 (enExample)
JP (1) JP2025515671A (enExample)
KR (1) KR20250008904A (enExample)
CN (1) CN119137131A (enExample)
AU (1) AU2023269038A1 (enExample)
CA (1) CA3252705A1 (enExample)
TW (1) TWI863271B (enExample)
WO (1) WO2023220123A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
KR102924836B1 (ko) 2020-03-30 2026-02-09 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
TWI778562B (zh) 2020-04-02 2022-09-21 美商基利科學股份有限公司 製備cot抑制劑化合物的方法
TW202523303A (zh) * 2023-12-11 2025-06-16 美商基利科學股份有限公司 用於治療發炎性腸道疾病之化合物及方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法

Also Published As

Publication number Publication date
AU2023269038A1 (en) 2024-11-28
KR20250008904A (ko) 2025-01-16
WO2023220123A1 (en) 2023-11-16
EP4522268A1 (en) 2025-03-19
TW202400161A (zh) 2024-01-01
TWI863271B (zh) 2024-11-21
CA3252705A1 (en) 2023-11-16
US20240174702A1 (en) 2024-05-30
CN119137131A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
US20240174702A1 (en) Solid forms of a compound for modulating cot
EP3962602B1 (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
US12459908B2 (en) Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
JP2021091736A (ja) Ａｃｃ阻害剤およびその固体形態を調製するためのプロセス
US20240010606A1 (en) Fumarate derivatives and their medical use
US20230381132A1 (en) Novel compounds
KR20180137497A (ko) N-｛6-(2-히드록시프로판-2-일)-2-[2-(메틸술포닐)에틸]-2h-인다졸-5-일｝-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 다형체 형태
WO2019140953A1 (zh) 用于抑制激酶活性的二苯氨基嘧啶类化合物
US20230399289A1 (en) Itaconic acid derivatives
KR20190002468A (ko) N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태
WO2022221642A1 (en) Thienopyrrole compounds
US20240360067A1 (en) Derivatives of itaconic acid and their use as anti-inflammatory agents
US20240245691A1 (en) 2-methylene-4-oxo-butanoic acid derivatives for the treatment of inflammation
AU2023392783A1 (en) Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
US20250333408A1 (en) Pyrimid-2-yl-pyrazole compounds as irak inhibitors
TW202317550A (zh) 作為jak抑制劑之咪唑吲唑化合物
HK40119474A (zh) 用於调节cot的化合物的固体形式
US20260138973A1 (en) Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
CN121358738A (zh) 调节irak4的化合物的盐和固体形式
EA049327B1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА
EA045296B1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260508